![]() ![]() With full understanding of the research showing Paxlovid helps reduce hospitalization and death in his and other age groups and among people with preexisting conditions, starting Paxlovid was a no-brainer for him. After a rapid test was positive for SARS-CoV-2, he began a five-day course of the three-pill Paxlovid regimen: two pink nirmatrelvir tablets and one white ritonavir tablet twice a day. #Pill reminder cases skin#On July 3, he told me he felt like a “rush going through my head, comparable to fever fantasies I had when I was a child,” and had developed a cough and highly sensitive skin all over his body - it hurt so much he could barely touch it. His days in Lindau were the culmination of five weeks he and his wife, Carol Saginaw, spent in Europe, packed with lectures, dinners, and scientific seminars. Joachim Frank had been in Germany for the 71st Lindau Nobel Laureate Meeting - a gathering of 30 or so Nobel laureates and select young scientists. My emergency medicine physician colleagues are seeing tons of it. In an email exchange, Ho characterized the frequency of rebound Covid as “common enough,” and that with more and more people taking Paxlovid, the number of rebound Covid cases will likewise increase. “I am Patient #2 and my family member is Patient #3,” he told me. By chance, he and a family member had recently experienced Covid rebound and, in fact, feature prominently in research findings of his that will soon be published in the New England Journal of Medicine. ![]() To offer my patients, family members, and friends the best advice possible, I reached out to David Ho, a virologist at Columbia University in New York who first figured out how HIV replicates and the go-to genius on many current virus issues. Since the CDC alert, there have been a number of rebound studies, including a recent investigation of 92 million people nationwide showing rebound rates of less than 6% for Covid infection - and less than 1% for hospitalizations after Paxlovid treatment - most occurring in unvaccinated people and in those with underlying medical conditions. Exclusive analysis of biotech, pharma, and the life sciences Learn More ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |